Trial · NCT03101033
Epidural Neuroplasty for the Treatment of Herniated Lumbar Disk
NCT03101033, Not applicable, Completed, yan lu; results first posted 2018-09-04
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Epidural Neuroplasty for the Treatment of Herniated Lumbar Disk. Trials, record NCT03101033. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03101033
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Epidural Neuroplasty for the Treatment of Herniated Lumbar Disk
- NCT number
- NCT03101033
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 92 participants, actual
- Lead sponsor
- yan lu
- Conditions
- Herniated Lumbar Disc
- Interventions
- Mechanical epidural neuroplasty, Transforaminal epidural compound betamethasone injection, Caudal epidural compound betamethasone injection, Epidural hyaluronidase injection
- First posted
- 2017-04-04
- Last updated
- 2018-09-04
- Results first posted
- 2018-09-04
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Assessed by Visual Analogue Scale | before treatment | VAS (Visual analogue scale), with the highest score of 10, representing the most severe pain one could experience, and the lowest score of 0, representing no pain at all. The higher score means more severe pain. |
| Primary | Pain Assessed by Visual Analogue Scale | at one-month post-treatment | VAS (Visual analogue scale), with the highest score of 10, representing the most severe pain one could experience, and the lowest score of 0, representing no pain at all. The higher score means more severe pain. |
| Primary | Pain Assessed by Visual Analogue Scale | at three-month post-treatment | VAS (Visual analogue scale), with the highest score of 10, representing the most severe pain one could experience, and the lowest score of 0, representing no pain at all. The higher score means more severe pain. |
| Primary | Pain Assessed by Visual Analogue Scale | at six-month post-treatment | VAS (Visual analogue scale), with the highest score of 10, representing the most severe pain one could experience, and the lowest score of 0, representing no pain at all. The higher score means more severe pain. |
| Secondary | Functional Status Assessed by Oswestry Disability Index | before treatment | ODI (Oswestry disability index) consists of 10 subscales, which evaluates pain intensity, and functional satus of personal care, lifting, walking, sitting, standing, sleeping, sex, social life, traveling. Each subscales range from 0 to 5, with the higher score indicating more severe functional damage. the ODI score ranges from 0 to 100. it equals the sum of all the subscales and divided by 50. If the patients answers 9 subscale questions, then the total sum should be divided by 45, and by this analogy. |
| Secondary | Functional Status Assessed by Oswestry Disability Index | at one-month post-treatment | ODI (Oswestry disability index) consists of 10 subscales, which evaluates pain intensity, and functional satus of personal care, lifting, walking, sitting, standing, sleeping, sex, social life, traveling. Each subscales range from 0 to 5, with the higher score indicating more severe functional damage. the ODI score ranges from 0 to 100. it equals the sum of all the subscales and divided by 50. If the patients answers 9 subscale questions, then the total sum should be divided by 45, and by this analogy. |
| Secondary | Functional Status Assessed by Oswestry Disability Index | at three-month post-treatment | ODI (Oswestry disability index) consists of 10 subscales, which evaluates pain intensity, and functional satus of personal care, lifting, walking, sitting, standing, sleeping, sex, social life, traveling. Each subscales range from 0 to 5, with the higher score indicating more severe functional damage. the ODI score ranges from 0 to 100. it equals the sum of all the subscales and divided by 50. If the patients answers 9 subscale questions, then the total sum should be divided by 45, and by this analogy. |
| Secondary | Functional Status Assessed by Oswestry Disability Index | at six-month post-treatment | ODI (Oswestry disability index) consists of 10 subscales, which evaluates pain intensity, and functional satus of personal care, lifting, walking, sitting, standing, sleeping, sex, social life, traveling. Each subscales range from 0 to 5, with the higher score indicating more severe functional damage. the ODI score ranges from 0 to 100. it equals the sum of all the subscales and divided by 50. If the patients answers 9 subscale questions, then the total sum should be divided by 45, and by this analogy. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Assessed by Visual Analogue Scale | before treatment | units on a scale | MEAN | |
| PRIMARY | Pain Assessed by Visual Analogue Scale | at one-month post-treatment | units on a scale | MEAN | |
| PRIMARY | Pain Assessed by Visual Analogue Scale | at three-month post-treatment | units on a scale | MEAN | |
| PRIMARY | Pain Assessed by Visual Analogue Scale | at six-month post-treatment | units on a scale | MEAN | |
| SECONDARY | Functional Status Assessed by Oswestry Disability Index | before treatment | units on a scale | MEAN | |
| SECONDARY | Functional Status Assessed by Oswestry Disability Index | at one-month post-treatment | units on a scale | MEAN | |
| SECONDARY | Functional Status Assessed by Oswestry Disability Index | at three-month post-treatment | units on a scale | MEAN | |
| SECONDARY | Functional Status Assessed by Oswestry Disability Index | at six-month post-treatment | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Assessed by Visual Analogue Scale | Epidural Neuroplasty Group | 5.63 | Standard Deviation 1.24 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Transforaminal Steroid Injection Group | 5.92 | Standard Deviation 1.20 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Epidural Neuroplasty Group | 2.37 | Standard Deviation 1.45 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Transforaminal Steroid Injection Group | 2.35 | Standard Deviation 1.40 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Epidural Neuroplasty Group | 2.19 | Standard Deviation 1.04 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Transforaminal Steroid Injection Group | 3.25 | Standard Deviation 1.57 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Epidural Neuroplasty Group | 2.81 | Standard Deviation 1.47 | units on a scale | |
| Pain Assessed by Visual Analogue Scale | Transforaminal Steroid Injection Group | 4.06 | Standard Deviation 1.76 | units on a scale | |
| Functional Status Assessed by Oswestry Disability Index | Epidural Neuroplasty Group | 53.85 | Standard Deviation 10.29 | units on a scale | |
| Functional Status Assessed by Oswestry Disability Index | Transforaminal Steroid Injection Group | 57.84 | Standard Deviation 9.63 | units on a scale |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Epidural Neuroplasty Group | 32 | |
| Overall Study | STARTED | Transforaminal Steroid Injection Group | 60 | |
| Overall Study | COMPLETED | Epidural Neuroplasty Group | 27 | |
| Overall Study | COMPLETED | Transforaminal Steroid Injection Group | 51 | |
| Overall Study | NOT COMPLETED | Epidural Neuroplasty Group | 5 | |
| Overall Study | NOT COMPLETED | Transforaminal Steroid Injection Group | 9 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | severe pain induced by the NP procedures in two participants | Surgical and medical procedures | Transforaminal Steroid Injection Group | 0 | 60 | 0 |
| other | severe pain induced by the NP procedures in two participants | Surgical and medical procedures | Epidural Neuroplasty Group | 2 | 32 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Transforaminal Steroid Injection Group | 0 | 60 |
| Total, all-cause mortality | Epidural Neuroplasty Group | 0 | 32 |
| Total, other adverse events | Transforaminal Steroid Injection Group | 0 | 60 |
| Total, other adverse events | Epidural Neuroplasty Group | 2 | 32 |
| Total, serious adverse events | Transforaminal Steroid Injection Group | 0 | 60 |
| Total, serious adverse events | Epidural Neuroplasty Group | 0 | 32 |
Source ClinicalTrials.gov
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Transforaminal Steroid Injection Group vs Epidural Neuroplasty Group: deaths from any cause | Trial comparisons |
| Transforaminal Steroid Injection Group vs Epidural Neuroplasty Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03101033
GET https://conductscience.org/api/trials/v1/NCT03101033/registered